Browse By

Tag Archives: TBP

Tetra Bio-Pharma Provides Additional Information on QIXLEEF Following Letter of Advice & Type B Meeting with USA FDA

QIXLEEF global market is expanded to include noncancer pain indications. Scientific approach to quality control of QIXLEEF validated by FDA.  OTTAWA, Feb. 24, 2020 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX-V: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and

Tetra Bio-Pharma Announces CAUMZ Program Update AND Expansion of Market Potential Following Type B Meeting with USA FDA

FDA conditions met for Fast Track designation – patient population has a serious condition with significant morbidity. Qualified for Accelerated Approval regulatory program – Tetra confirms Patient-Reported Outcome (PRO) instrument is a validated surrogate endpoint. CAUMZ to be reviewed under the 505(b)(2) pathway – leverage